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Abstract Wheat gliadin and other cereal prolamins have been
said to be involved in the pathogenic damage of the small intes-
tine in celiac disease via the apoptosis of epithelial cells. In the
present work we investigated the mechanisms underlying the
pro-apoptotic activity exerted by gliadin-derived peptides in
Caco-2 intestinal cells, a cell line which retains many morpho-
logical and enzymatic features typical of normal human entero-
cytes. We found that digested peptides from wheat gliadins (i)
induce apoptosis by the CD95/Fas apoptotic pathway, (ii) in-
duce increased Fas and FasL mRNA levels, (iii) determine in-
creased FasL release in the medium, and (iv) that gliadin digest-
induced apoptosis can be blocked by Fas cascade blocking
agents, i.e. targeted neutralizing antibodies. This favors the hy-
pothesis that gliadin could activate an autocrine/paracrine Fas-
mediated cell death pathway. Finally, we found that (v) a small
peptide (1157 Da) from durum wheat, previously proposed for
clinical practice, exerted a powerful protective activity against
gliadin digest cytotoxicity.
. 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Apoptosis is central to the maintenance of the epithelial
functions of the gut as it is involved in the normal enterocyte
turnover. Under physiological conditions apoptotic cells are
restricted to the tips of the villous in the small bowel and are
replaced by an equal number of proliferating immature crypt
cells [1]. In contrast, in immuno-mediated disorders such as
in£ammatory bowel disease or celiac disease (CD), an in-
creased number of enterocytes undergo premature apoptosis
all along the crypt^villous axis [2,3]. The combination of
markedly increased apoptosis and altered turnover rates re-
sults in architectural changes in the mucosa, characterized by
villous atrophy and crypt hyperplasia. CD and its symptoms,
observed in genetically predisposed individuals, are due to the
ingestion of the bread wheat prolamin fraction gliadin, as well
as the corresponding prolamin fractions of rye, barley and
probably oats [4^6]. The mechanism by which these cereal
prolamin fractions, whose toxicity is not destroyed by diges-
tion with gastropancreatic enzymes, damage the celiac small
intestine is not clear yet. Although it is largely accepted that
an altered immune response to prolamin-derived peptides is
involved in the pathogenesis and the progression of CD [7^9],
a direct non-immune-mediated activity of gliadin-derived pep-
tides on the jejunal/duodenal tract was also hypothesized.
Several studies, in fact, support the hypothesis that wheat
gliadin displays a direct cytotoxic activity against enterocytes
and that this is inversely correlated with the di¡erentiation
state of the cells [10^12]. For instance, it was shown that
gliadin was also capable of inducing cytotoxic e¡ects on cul-
tured intestinal biopsy specimens obtained from celiac pa-
tients with activation of lamina propria T lymphocytes and
macrophages [13]. We have previously demonstrated that the
treatment of human intestinal cells in culture (Caco-2)
throughout their early phases of di¡erentiation with gliadin-
derived peptides from bread wheat resulted in cytotoxic ef-
fects, such as membrane damage, impairment of cell prolifer-
ation and cell di¡erentiation, cell detachment and cell death
by apoptosis [14^16]. On the other hand, we had shown that a
small peptide with 1157 Da molecular weight, identi¢ed as
the sequence H2N-gln-gln-pro-gln-asp-ala-val-gln-pro-phe-
COOH, not only was able to prevent the cytotoxicity [17,18]
induced by peptic-tryptic (PT) digests of prolamin fractions
from the cereals that are not tolerated by celiac patients, but
also counteracts all the cytotoxic e¡ects described above for
the Caco-2 cell line [16]. As we described elsewhere, this pep-
tide was characterized and identi¢ed from a gliadin compo-
nent of durum wheat, and seems to be responsible for its
lesser toxic activity, as resulted from studies performed in
vitro [17]. We felt this peptide would eventually become the
focus of interest in the clinical practice [16^18]. The aim of the
present work was thus to investigate the mechanisms under-
lying the apoptosis induced by gliadin-derived peptides in
Caco-2 cells, exposing the cells to the PT digest of the bread
wheat gliadin (Gl^PT), mimicking intestinal physiological
conditions. Since the Caco-2 cell line retains many of the
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morphological and enzymatic features typical of normal hu-
man enterocytes [19,20], it is largely used as a model system
for evaluating the e¡ects of normal dietary constituents as
well as additives, contaminants, toxicants, oxidants and drugs
[21,22]. In the present work we found that (i) gliadin-derived
peptides are potent and speci¢c inducers of receptor-mediated
apoptosis in human colon cells via a target activity on Fas/
FasL pathway, and (ii) this apoptotic proneness can be sig-
ni¢cantly counteracted by the administration of the ‘1157 Da’
peptide derived from durum wheat.
2. Materials and methods
2.1. Peptic-triptic (PT) digest
The gliadin fraction was extracted from whole cereal £our of bread
wheat (Triticum aestivum, S. Pastore variety) as previously described
by Auriccchio et al. [12]. The gliadin fraction or bovine serum albu-
min (BSA) (used as an inactive control protein), were subjected to
sequential digestion according to de Ritis et al. [11], to obtain the
corresponding PTs. At the end of the procedure, PTs were heated
for 30 min at 100‡C, lyophilized and stored at 320‡C.
2.2. ‘1157 Da’ peptide
The peptide with molecular weight 1157 Da was identi¢ed from
gliadin of durum wheat (Adamello variety) as previously described
[17]. The peptide was synthesized by Primm Company (Milan, Italy)
with the solid phase method using the Applied Biosystems model
431 A, and was puri¢ed up to s 99% by reverse-phase high-perfor-
mance liquid chromatography (RT-HPLC) on a Varian 5020 system
[17].
2.3. Cell cultures
The human colon cell line Caco-2 was obtained from the European
Collection of Cell Cultures (Salisbury, UK). Cells were grown in
Dulbecco’s modi¢ed Eagle’s medium (DMEM; Hyclone, Cramling-
ton, UK) with 4.5 g glucose per liter, supplemented with 1% (v/v)
non-essential amino acids (Flow Laboratories, Irvine, Scotland,
UK), 0.2 mM L-glutamine (Flow Labs), 50 U/ml penicillin (Flow
Labs), 50 Wg/ml streptomycin (Flow Labs), and 10% (v/v) fetal calf
serum (Flow Labs), at 37‡C in a humidi¢ed atmosphere of 5% CO2 in
air.
2.4. Experimental procedures and treatments
For each experiment 5U105 cells were seeded in 25 cm2 tissue cul-
ture £asks (Falcon, Becton Dickinson, Meylan, France) as previously
described [17]. On culture day 5, di¡erentiating Caco-2 cell mono-
layers were washed and treated as described below. Cell number
was evaluated daily with a ZM Coulter Counter (Coulter Electronics,
Luton, UK). PT digest : Gl^PT digest or BSA^PT digest, dissolved in
the medium, were sterilized by ¢ltration through a 0.2 Wm Millipore
membrane (Millipore, Bedford, MA, USA) and added to 5-day cul-
tures at a ¢nal concentration of 1 mg/ml as previously reported [16]
for 6, 12, 18, 24 and 48 h. The PT digest from BSA was used as
inactive control. ‘1157 Da’ peptide : The ‘1157 Da’ peptide was ad-
ministered in the sterile medium 2 h before exposure to Gl^PT digest,
and maintained in the culture medium during treatments. The PT
digests and ‘1157 Da’ peptide concentrations used in the present in-
vestigation were chosen on the basis of experiments previously pub-
lished by our group [14^16]. Fas : Cell cultures were incubated with (i)
15 ng/ml anti-Fas activating antibody (clone CH11); (ii) 1Wg/ml anti-
Fas inhibiting antibody (clone ZB4) (Upstate Biotechnology, Lake
Placid, NY, USA) 2 h before exposure to Gl^PT digest; (iii) 2 Wg/
ml anti-FasL inhibiting antibody (clone NOK-1) (Pharmingen, San
Diego, CA, USA) 2 h before exposure to Gl^PT digest. As further
control, either mouse IgM (control for Fas-triggering) or mouse IgG1
(control for Fas- and for FasL-neutralizing) were also considered.
caspase inhibitors : 2 h before the apoptotic stimuli described above,
100 WM DEVD-CHO (Asp-Glu-Val-Asp-aldehyde; cell permeant cas-
pase-3 inhibitor), LEHD-CHO (Leu-Glu-His-Asp-aldehyde; cell per-
meant caspase-9 inhibitor), or IETD-CHO (Ile-Glu-Thr-Asp-alde-
hyde; cell permeant caspase-8 inhibitor) (Biosource International,
Camarillo, CA, USA) were directly added to the culture medium.
Cells treated with caspase inhibitors alone were used as controls.
2.5. Apoptosis evaluation
Apoptosis was quantitatively evaluated by the following £ow and
static cytometry methods: (i) double staining by using annexin
V-FITC and propidium iodide (PI) (ApoAlert Annexin V apoptosis
kit; Clontech Laboratories, Palo Alto, CA, USA) according to the
manufacturer’s instructions. Two-color cytometric analysis (£uores-
cence-activated cell sorting [FACS]) was performed on a Coulter Ep-
ics Elite ESP cell sorter (Miami, FL, USA) with an argon-ion laser
tuned at 488 nm; (ii) staining with chromatin dye Hoechst (Molecular
Probes) as previously described [23].
2.6. Intracellular redox state
Control and treated cells (5U105) were harvested and incubated in
495 Wl of Hanks’ balanced salt solution (pH 7.4) with hydroetidine
(HE; Molecular Probes), dihydrorhodamine 123 (DHR 123; Molec-
ular Probes) or 5-chloromethyl-2P,7P-dichloro-dihydro£uoresceindia-
cetate (CM-H2DCFDA, Molecular Probes) for detection of superox-
ide anion, hydrogen peroxide and GSH, respectively. After 15 min at
37‡C samples were analyzed on a cytometer as previously described
[24].
2.7. Human lymphocyte experiments
Activated human lymphocytes (6000 IU IL2+0.5 Wg/ml PHA for
48 h) were triggered by 500 ng/ml of K-Fas (clone CH11) in the
presence or absence of two di¡erent concentrations of peptide 1157
(0.5 mg/ml or 1 mg/ml). Aliquots of cells were removed after 48 and
72 h and analyzed by £ow cytometry for apoptosis after annexin V/PI
double staining.
2.8. Evaluation of cell death molecules
Surface and intracytoplasmic expression of CD95/Fas and Fas li-
gand were veri¢ed by £ow cytometry using speci¢c monoclonal anti-
body (MAb). For evaluation of surface antigens control and treated
Caco-2 cells were incubated on ice with anti-CD95 (Becton Dickinson,
Mountain View, CA, USA) or with anti-Fas ligand (Pharmingen).
After 1 h at 4‡C, samples and isotypic controls were washed and
incubated for 30 min with FITC-labeled anti-mouse (Sigma). For
intracellular evaluation, Caco-2 cells were pelleted and ¢xed in 70%
ice-cold methanol. After washing, samples were stained with the same
MAb for 1 h at 37‡C and then with FITC-labeled anti-mouse (Sigma)
for an additional 30 min. After washing, cells were analyzed with a
FACScan £ow cytometer (Becton Dickinson) equipped with a 488
argon laser. At least 20 000 events have been acquired. Data were
recorded and statistically analyzed by a Macintosh computer using
CellQuest Software.
2.9. Extraction of total RNA and semiquantitation by reverse
transcriptase-polymerase chain reaction (RT-PCR)
Total RNA from cultured Caco-2 was extracted by the Trizol (Gib-
co BRL, Grand Island, NY, USA) isolation method. 1 Wg of total
RNA was used for RT-PCR analysis. PCR was performed using the
following couples of primers: 5P-CCC AAA TAG GAG TGT ATG
CAG AGG-3P and 5P-GCC ATT AAG ATG ACC AAG G-3P for
ampli¢cation of FAS; 5P-CCA CCG CCA CCA CTA CCA-3P and 5P-
TCT TCC CCT CCA TCA TCA CC-3P for FAS ligand; 5P-CCA
CCC ATG GCA AAT TCC ATG GCA-3P and 5P-TCT AGA CGG
CAG GTC AGG TCC ACC-3P for ampli¢cation of GAPDH as
housekeeping gene. The samples were incubated in an automated
heat-block Minicycler (MJ Research, Waltham, MA, USA) by using
the following parameters: 95‡C for 30 s, 68‡C for 90 s and 72‡C for
90 s using 42 cycles (Fas), and 94‡C for 60 s, 59‡C for 60 s and 72‡C
for 120 s using 34 cycles (FasL). The PCR products were electropho-
resed on a 1.5% agarose gel containing ethidium bromide. Densito-
metric analysis was performed by a FX molecular imager (Bio-Rad,
Hercules, CA, USA).
2.10. Assay of Fas ligand in Caco-2 cell supernatants
Fas ligand concentrations in the supernatants of Caco-2 cells were
evaluated by sensitive and speci¢c immunoassays, using commercial
ELISA kits (RpD Systems, Minneapolis, MN, USA). Caco-2 cells,
seeded as described above, were exposed to Gl^PT alone or Gl^
PT+1157 Da for di¡erent times. Supernatant aliquots were removed
after 6, 18, 24 and 48 h of treatment and assayed for Fas ligand
content according to the manufacturer’s instructions.
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2.11. Statistical analysis
The data are presented as the arithmetic mean for each experi-
mental pointX S.E.M. Statistical calculations were performed using
a one-way ANOVA. Di¡erences among groups were examined
using the Bonferroni t-test when the F value was signi¢cant. A P
value 6 0.05 was considered signi¢cant.
3. Results
3.1. Gliadins impair cell homeostasis by inducing apoptosis in
Caco-2 cells
We considered subcellular activity of Gl^PT by studying
cell death by apoptosis, evaluated by annexin-V/PI double
staining to detect early apoptotic events clearly. Quantitative
analyses over six di¡erent experiments indicated a signi¢cant
increase (P6 0.01) of the apoptotic phenomenon after 24 and
48 h of Gl^PT exposure with respect to control cells (a 3.7-
and 3.9-fold increase, respectively) (Fig. 1A). However, a low-
er apoptotic rate was detected after 48 h with respect to 24 h
of Gl^PT exposure, owing to the increased amount of necrotic
cells, as reported in Fig. 1B, right panel, second quadrant. It is
noteworthy to underline that the increase of apoptotic cells,
observed in Gl^PT-treated Caco-2 cultures, was accompanied
by a signi¢cant reduction of counted cells. In fact, cell number
per £ask was 35U105 X 44U104 and 66U105 X 14U104 in
treated cells, 43U105 X 52U104 and 82U105 X 17U104 in con-
trol cells at 24 and 48 h, respectively. The analysis of apopto-
Fig. 1. Pro-apoptotic e¡ects of Gl^PT digest in intestinal cells. A: Quantitative analysis of apoptotic phenomenon. Values reported in the graph
correspond to the percentage of single annexin V-positive cells (early apoptosis). *P6 0.001: Gl^PT vs. control cells (CTR), BSA^PT-digest-ex-
posed cells (BSA^PT), Gl^PT-digest-treated cells (Gl^PT) and Gl^PT digest-treated cells preincubated with the ‘1157 Da’ peptide (Gl^
PT+1157). Values are expressed as meanXS.E.M. of six independent experiments. B: Evaluation of apoptosis by FACs analysis of annexin V/
PI double positive Caco-2 cells in: control cells (CTR, left panel), Gl^PT for 24 h (middle panel) and 48 h (right panel). Note the increase in
necrotic cells after 48 h of Gl^PT treatment (second quadrant in the right panel). One experiment representative of four is shown. C: Fluores-
cence microscopy of adhering Caco-2 cell nuclei stained with Hoechst 33258. Left panel: control cells ; middle panel: 24 h Gl^PT treated cells ;
right panel: 48 h Gl^PT treated cells. The arrows indicate chromatin condensation or clumping typical of apoptosis. Note the decreased cell
density in 48 h Gl^PT treated cells.
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tic nuclei of adhering cells with Hoechst £uorescent dye con-
¢rmed these observations. Control cells (Fig. 1C, left panel)
showed intact nuclei without any sign of chromatin conden-
sation typical of apoptosis. After 24 h, Gl^PT induced chro-
matin aggregation and/or clumping in some of cells (Fig. 1B,
middle panel, arrows). Prolonging the treatment with Gl^PT
up to 48 h, we observed: (i) the presence of nuclei with clear
signs of apoptosis (Fig. 1C, right panel, arrows), and (ii) the
reduction of cell density caused by cell detachment from the
substrate.
No signi¢cant di¡erence in apoptosis rate was found using
BSA-PT digest (BSA^PT) as further control: the percentage
of apoptotic cells was similar to that of control samples (8.6%)
(Fig. 1A). The e¡ects of the pre-treatment with the ‘1157 Da’,
a small peptide from a gliadin component of durum wheat
with 1157 Da molecular weight, was also taken into account.
This agent fully counteracted the pro-apoptotic activity of Gl^
PT, being the percentage of apoptotic cells comparable to that
of control samples (Fig. 1A).
3.2. Gliadins induce redox imbalance in intestinal cells as
a late event
Considering that redox imbalance can be an important
event in apoptotic cell death, time course experiments were
carried out by £ow cytometry to evaluate the intracellular
production of reactive oxygen species (ROS; speci¢cally
superoxide anions and hydrogen peroxide) and GSH content.
For this purpose we used speci¢c probes, namely HE (for
detection of O32 ), DHR 123 (for detection of H2O2) and
CM-H2DCFDA (for GSH measurements). Soon after Gl^
PT treatment (6, 12 and 18 h), no changes in O32 , H2O2
production or GSH content were detected (data not shown).
By contrast, as expected, once the apoptotic process was evi-
dent by £ow cytometry analyses, i.e. as from 24 h after ex-
posure to Gl^PT, we observed a signi¢cant (P6 0.01) increase
in O32 (+98X 9%) and in H2O2 (+70X6%) production as well
as a decrease (382%) in GSH content with respect to un-
treated cells. These values were obtained by comparing the
median values of the respective £uorescence intensity histo-
grams and considering the median value of control untreated
cells as 100%. These results suggest that redox imbalance is a
tardive event, playing a secondary role in Gl^PT-induced ap-
optosis.
3.3. Gliadin-induced apoptosis is mediated by the
receptor-mediated pathway
To elucidate the subcellular pathway involved in Gl^PT-
induced apoptosis in Caco-2 cells, a series of experiments on
the caspase cascade was carried out. We ¢rst considered the
upstream caspases that are involved in the initiation phase of
apoptosis, i.e. caspase-8 (mainly involved in receptor-medi-
ated apoptosis) and caspase-9 (mainly involved in mitochon-
dria-mediated apoptosis) [25]. In fact, experiments with cas-
pase-8 and caspase-9 inhibitors clearly indicated that caspase-
8 inhibitor IETD-CHO fully inhibited Gl^PT-induced apopto-
sis, while LEHD-CHO, a caspase-9 inhibitor, did not exert
any protective e¡ect. The activity of caspase-3, an executioner
downstream caspase, was also assessed by using the speci¢c
inhibitor DEVD-CHO. This compound reduced the Gl^PT-
induced apoptosis by 85% (Fig. 2A). These results clearly
indicate that the apoptosis induced by Gl^PT in Caco-2 in-
testinal cells may occur via the classical caspase cascade acti-
vation and, more importantly, that the receptor-mediated ap-
optotic pathway involving caspase-8 activation plays a key
role.
3.4. Gliadins induce apoptosis via the Fas/FasL pathway
Among cell death receptors, the Fas/APO-1/CD95 receptor
was demonstrated to be widely expressed by many cell types,
including enterocytes [26]. Its activation was recently reported
to be responsible for enterocyte death by apoptosis in CD
[27,28]. As veri¢ed by £ow cytometry, Caco-2 intestinal cells
do express the Fas molecule on their surface (median value of
the £uorescence intensity histogram 27.4 X 5). To evaluate the
involvement of the Fas-mediated pathway in Gl^PT-induced
apoptosis, cultured Caco-2 cells were incubated with anti-Fas
activating antibody (clone CH11) and, more importantly, with
anti-Fas neutralizing antibody or anti-FasL neutralizing anti-
body in the presence and absence of the gliadin. The results
obtained (Fig. 2B) indicated that anti-Fas antibody triggered
apoptosis in Caco-2 cells, and that the percentage of apoptotic
cells was signi¢cantly reduced by the presence of anti-Fas
neutralizing antibodies (clone ZB4) in the medium. This
clearly identi¢ed Caco-2 cells as typical Fas-susceptible cells.
Interestingly, when the cells were induced to undergo apopto-
sis by Gl^PT treatment in the presence of anti-Fas neutraliz-
ing antibodies, apoptosis was fully inhibited and normal ap-
optotic control values were restored. On the basis of these
results, we focused further analyses on FasL apoptotic cas-
cade. What we found was that anti-FasL neutralizing anti-
bodies (clone NOK-1) were also able to signi¢cantly counter-
act Gl^PT-induced apoptosis, clearly proving the involvement
of the Fas/FasL pathway in the Gl^PT-mediated apoptotic
cascade. Interestingly, the presence of the ‘1157 Da’ peptide
in Caco-2 cell cultures, which was able to protect from Gl^
PT-induced apoptosis (see Fig. 1A), also hindered anti-Fas
induced apoptosis, signi¢cantly reducing the percentage of
apoptotic cells by 42X 3% (P6 0.01) (Fig. 2B). As a further
control, in consideration of the plethora of data in the liter-
ature indicating human lymphocytes as the milestone of phys-
iological Fas-induced apoptosis, the pro-apoptotic activity ex-
erted by Gl^PT and the anti-apoptotic activity of the ‘1157
Da’ peptide were also evaluated in freshly isolated human
activated lymphocytes. As with intestinal Caco-2 cells, a sig-
ni¢cant increase in the percentage of apoptotic cells was de-
tected after treatment with Gl^PT as well as with CH11 anti-
bodies (Fig. 2C). Moreover, an anti-apoptotic activity of the
‘1157 Da’ peptide versus CH11-mediated apoptosis was also
detected (Fig. 2C). Altogether, these results seem to indicate
that Gl^PT and the small peptide from durum wheat can
exert their activity, i.e. pro-apoptotic and anti-apoptotic, re-
spectively in cells belonging to a di¡erent histotype.
3.5. Target activity of gliadin on the Fas-mediated pathway
To understand how Gl^PT could activate the Fas/FasL ap-
optotic pathway in Caco-2 cells, we conducted a series of time
course experiments focused on the Fas and FasL gene expres-
sion. As reported in Fig. 3A,B, the results obtained by RT-
PCR showed a signi¢cant overtranscription of both genes,
Fas (agarose gel electrophoresis in Fig. 3A) and FasL (aga-
rose gel electrophoresis in Fig. 3B). In fact, densitometric
analyses of cells exposed to Gl^PT showed a highly signi¢cant
(P6 0.001) increase in Fas (450%) and FasL (170%) mRNA
expression with respect to control values at every time point
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(6, 18, 24 h). Strikingly, but in agreement with the results
reported above, the presence of the ‘1157 Da’ peptide in the
medium of Caco-2 cell cultures restored the control mRNA
values for both Fas and FasL, wholly counteracting the e¡ects
of Gl^PT (Fig. 3A,B).
3.6. Gliadins induced secretion of soluble FasL
On the basis of the above results, we investigated whether
the increase in FasL mRNA detected after Gl^PT exposure
(Fig. 3B) also resulted in the production and release of the
FasL molecule in the culture medium. Interestingly, an in-
Fig. 2. Gliadins induce apoptosis mediated by caspase-8 and -3 via Fas/FasL pathway. A: Quanti¢cation of Gl^PT-digest-induced apoptosis in
the absence and presence of DEVD-CHO (caspase-3 inhibitor) (Gl^PT+DEVD-CHO); LEHD-CHO (caspase-9 inhibitor) (Gl^PT+LEHD-
CHO); or IETD-CHO (caspase-8 inhibitor) (Gl^PT+IETD-CHO). Values are expressed as meanXS.E.M. of four independent experiments.
*P6 0.001: Gl^PT vs. Gl^PT+DEVD-CHO; Gl^PT vs. Gl^PT+IETD-CHO. B: Quanti¢cation of apoptosis in Caco-2 cells incubated with:
(i) anti-Fas inhibiting antibody, clone ZB4, 2 h before Gl^PT digest exposure (Gl^PT+ZB4); (ii) anti-FasL inhibiting antibody, clone NOK-1,
2 h before Gl^PT digest exposure (Gl^PT+NOK-1); (iii) anti-Fas activating antibody, clone CH11, (CH11); (iv) anti-Fas activating antibody,
clone CH11, + anti-Fas inhibiting antibody, clone ZB4, (CH11+ZB4); (v) anti-Fas activating antibody, clone CH11, + the ‘1157 Da’ peptide
(CH11+1157). The percentages of annexin-V positive cells 24 h after apoptotic triggering are reported as meanXS.E.M. of four independent ex-
periments. *P6 0.001: Gl^PT+ZB4 vs. Gl^PT; Gl^PT+NOK-1 vs. Gl^PT; CH11+ZB4 vs. CH11. **P6 0.01: CH11+1157 vs. CH11. C: Eval-
uation of apoptosis induced in human activated lymphocytes by Gl^PT at the same concentration used in Caco-2 cells and by anti-Fas activat-
ing antibodies (CH11) in the presence/absence of two concentrations of the ‘1157 Da’ peptide for 48 and 72 h. Note the signi¢cant reduction
of apoptotic rate induced by the 1157 peptide. *P6 0.01: CH11+1157 (1 mg/ml) vs. CH11.
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creased secretion of FasL was found starting within 6 h after
Gl^PT exposure (P6 0.05). FasL production increased fur-
ther after 24 and 48 h of Gl^PT treatment (P6 0.01). When
the e¡ects of the protecting ‘1157 Da’ peptide were assessed, a
complete inhibition of Gl^PT-mediated FasL release was
found, the values detected being quite similar to those found
in control samples (Fig. 3C).
4. Discussion
The importance of apoptosis in tissue homeostasis has been
demonstrated in numerous diseases, including intestinal dis-
metabolic degenerative diseases. Among these, increased apo-
ptosis was related to mucosal £attening occurring in CD.
Namely, an increased apoptosis rate has been hypothesized
as the major factor responsible for villous atrophy in CD.
The novelty of the present work is that after PT digestion
gliadin bread wheat peptides induced apoptosis by directly
acting via the ‘activation’ of an autocrine/paracrine mecha-
nism involving FasL production. As a general rule, apoptosis
has been described as mediated by two pathways that,
although strictly intertwined, represent di¡erent ways to reach
the same result, i.e. the death of a cell [29,30]. One pathway
(receptor-mediated) mainly involves caspase-8 activation; the
Fig. 3. Gliadins induce upregulation of the Fas/FasL system by increasing mRNA transcription and secretion of soluble FasL. Quantitative
evaluation of Fas (panel A) and Fas/L (panel B) mRNA transcription by RT-PCR, reported as optical density (OD). Values are the meanX
S.E.M. of four independent time-course experiments in duplicate, observed in untreated control cells (CTR), in Gl^PT and in Gl^PT-treated
cells preincubated with the ‘1157 Da’ peptide (Gl^PT+1157) at di¡erent exposure times. *P6 0.001: Gl^PT vs. CTR; Gl^PT vs. Gl^PT+1157.
A representative agarose gel obtained by RT-PCR from four independent experiments is shown, for Fas (panel A) and Fas/L (panel B). C: Re-
lease of soluble FasL in the culture medium appears signi¢cantly increased after 24 and 48 h of cell exposure to Gl^PT. The small peptide
1157 signi¢cantly impaired Gl^PT-induced FasL secretion. *P6 0.01: Gl^PT vs. CTR.
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other was shown to be primarily linked to mitochondrial
changes and the activation of caspase-9, with release of cyto-
chrome c into the cytosol and apoptosome complex formation
[31^33]. Both caspase-8 and caspase-9 ¢nally activate caspase-
3 by proteolytic cleavage, and, in turn, caspase-3, one of the
key executioners of apoptotic cell death, cleaves vital cellular
proteins [25,34]. Our results, obtained with speci¢c caspase
inhibitors and neutralizing antibodies, appear to indicate
that Gl^PT-induced apoptosis is speci¢cally mediated by
CD95/Fas and it is under the control of caspase-8. We also
found that Caco-2 intestinal cells, in the absence of any treat-
ment, were able to express the CD95/Fas receptor and pro-
duce per se its ligand, FasL. However, these high basal levels
did not result in high apoptotic rates. We can hypothesize that
a sort of threshold should be surpassed for Caco-2 cells to
undergo apoptosis. In fact, when exposed to gliadin, Fas re-
ceptor expression increased signi¢cantly as well as FasL pro-
duction, though to a lesser extent. As a result, high apoptotic
rates were detected. Hence, the hypothesis of a gliadin-medi-
ated autocrine mechanism leading to cell degeneration can be
reasonably considered. In the same vein, Ciccocioppo et
al.[27] suggested that Fas/Fas ligand-mediated enterocyte ap-
optosis was involved in mucosal £attening in CD, as resulting
from the overexpression of the Fas receptors on enterocytes
and Fas ligand on lymphocytes in celiac mucosa. It was also
suggested [28] that gliadin might be directly responsible for
Fas upregulation, playing a pivotal role in epithelial damage.
Hence, we can hypothesize that gliadin might function as an
apoptosis-sensitizing compound, boosting speci¢c intracellular
processes [27,28,35] and increasing intestinal cell apoptotic
proneness. Our results were obtained with the Caco-2 cell
line widely used as a suitable in vitro model for pharmacotox-
icologic studies regarding the intestine [36^38] and, more re-
cently, to address the dysregulated intestinal function speci¢-
cally related to CD [39^41]. Hence, our results, albeit in vitro,
seem to provide helpful suggestions regarding the pathoge-
netic mechanisms underlying CD.
In the present work we also show that a small peptide from
a gliadin component of durum wheat can exert powerful pro-
tective e¡ects. This compound was actually capable of pro-
tecting intestinal cells from both Gl^PT- and Fas antibodies-
induced apoptosis, probably by impairing Fas/FasL trigger-
ing. In addition, it inhibited Fas-mediated apoptosis in freshly
isolated human activated T lymphocytes. This is an interesting
¢nding in view of future studies aimed at the understanding of
the immune modulating activities exerted by Gl^PT. As re-
ported by several in vitro and in vivo studies [42^45], the
sequences -Gln-Gln-Gln-Pro- and/or -Pro-Ser-Gln-Gln- are
known to be a common feature of toxic gliadin-derived pep-
tides. Interestingly, remarkable homologies were identi¢ed be-
tween these toxic sequences and the protective amino acid
sequence within the ‘1157 Da’ peptide (H2N-gln-gln-pro-gln-)
[17,18,40]. This could suggest that this peptide could be
recognized by the same (or structurally-related) binding sites
on the cell surface. It is thus likely to interfere with the apo-
ptotic switch by inhibiting the sequence of biological events
leading to Fas^FasL-mediated cell death. Further investiga-
tions are under way to elucidate the mechanism by which this
peptide interferes with intestinal cell fate. If the protective
activity exerted by the ‘1157 Da’ peptide is con¢rmed by in
vivo studies, new clinical perspectives will be opened in the
management of CD.
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